Vitamin C in combination with inhibition of mutant IDH1 synergistically activates TET enzymes and epigenetically modulates gene silencing in colon cancer cells

References

• Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000 Apr;16(4):168–174.
   PubMed Web of Science ®Google Scholar
• Eden A, Gaudet F, Waghmare A, et al. Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 2003 Apr 18;300(5618):455.
   PubMed Web of Science ®Google Scholar
• Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol. 2016 Sep 1;8(9).
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010 Dec 14;18(6):553–567.
   PubMed Web of Science ®Google Scholar
• Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012 Feb 15;483(7390):474–478.
   PubMed Web of Science ®Google Scholar
• Zheng S, Houseman EA, Morrison Z, et al. DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. Neuro Oncol. 2011 Mar;13(3):280–289.
   PubMed Web of Science ®Google Scholar
• Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009 May 15;324(5929):930–935.
   PubMed Web of Science ®Google Scholar
• Ito S, D’Alessio AC, Taranova OV, et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. 2010 Aug 26;466(7310):1129–1133.
   PubMed Web of Science ®Google Scholar
• Ito S, Shen L, Dai Q, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011 Sep 2;333(6047):1300–1303.
   PubMed Web of Science ®Google Scholar
• He YF, Li BZ, Li Z, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science. 2011 Sep 2;333(6047):1303–1307.
   PubMed Web of Science ®Google Scholar
• Hu L, Li Z, Cheng J, et al. Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation. Cell. 2013 Dec 19;155(7):1545–1555.
   PubMed Web of Science ®Google Scholar
• Pastor WA, Aravind L, Rao A. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat Rev Mol Cell Biol. 2013 Jun;14(6):341–356.
   PubMed Web of Science ®Google Scholar
• Lian CG, Xu Y, Ceol C, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell. 2012 Sep 14;150(6):1135–1146.
   PubMed Web of Science ®Google Scholar
• Delatte B, Deplus R, Fuks F. Playing TETris with DNA modifications. Embo J. 2014 Jun 2;33(11):1198–1211.
   PubMed Web of Science ®Google Scholar
• Hore TA, von Meyenn F, Ravichandran M, et al. Retinol and ascorbate drive erasure of epigenetic memory and enhance reprogramming to naive pluripotency by complementary mechanisms. Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12202–12207.
   PubMed Web of Science ®Google Scholar
• Minor EA, Court BL, Young JI, et al. Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine. J Biol Chem. 2013 May 10;288(19):13669–13674.
   PubMed Web of Science ®Google Scholar
• Monfort A, Wutz A. Breathing-in epigenetic change with vitamin C. EMBO Rep. 2013 Apr;14(4):337–346.
   PubMed Web of Science ®Google Scholar
• Blaschke K, Ebata KT, Karimi MM, et al. Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature. 2013 Aug 8;500(7461):222–226.
   PubMed Web of Science ®Google Scholar
• Coulter JB, O’Driscoll CM, Bressler JP. Hydroquinone increases 5-hydroxymethylcytosine formation through ten eleven translocation 1 (TET1) 5-methylcytosine dioxygenase. J Biol Chem. 2013 Oct 4;288(40):28792–28800.
   PubMed Web of Science ®Google Scholar
• Yin R, Mao SQ, Zhao B, et al. Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals. J Am Chem Soc. 2013 Jul 17;135(28):10396–10403.
   PubMed Web of Science ®Google Scholar
• Ko M, An J, Pastor WA, et al. TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunol Rev. 2015 Jan;263(1):6–21.
   PubMed Web of Science ®Google Scholar
• Turcan S, Makarov V, Taranda J, et al. Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. Nat Genet. 2018 Jan 01;50(1):62–72.
   PubMed Web of Science ®Google Scholar
• Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008 Dec;116(6):597–602.
   PubMed Web of Science ®Google Scholar
• Bleeker FE, Lamba S, Leenstra S, et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat. 2009 Jan;30(1):7–11.
   PubMed Web of Science ®Google Scholar
• Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013 Apr 15;27(8):836–852.
   PubMed Web of Science ®Google Scholar
• Miller JJ, Shih HA, Andronesi OC, et al. Isocitrate dehydrogenase-mutant glioma: evolving clinical and therapeutic implications. Cancer. 2017;123(23):4535–4546.
   PubMed Web of Science ®Google Scholar
• Whitehall VL, Dumenil TD, McKeone DM, et al. Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype. Epigenetics. 2014 Nov;9(11):1454–1460.
   PubMed Web of Science ®Google Scholar
• Chowdhury R, Yeoh KK, Tian YM, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011 May;12(5):463–469.
   PubMed Web of Science ®Google Scholar
• Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009 Dec 10;462(7274):739–744.
   PubMed Web of Science ®Google Scholar
• Koivunen P, Lee S, Duncan CG, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012 Feb 15;483(7390):484–488.
   PubMed Web of Science ®Google Scholar
• Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011 Jan 18;19(1):17–30.
   PubMed Web of Science ®Google Scholar
• Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010 May 18;17(5):510–522.
   PubMed Web of Science ®Google Scholar
• Khurshed M, Molenaar RJ, Lenting K, et al. In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma. Oncotarget. 2017 Jul 25;8(30):49165–49177.
   PubMedGoogle Scholar
• Grassian AR, Parker SJ, Davidson SM, et al. IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. Cancer Res. 2014 Jun 15;74(12):3317–3331.
   PubMed Web of Science ®Google Scholar
• Izquierdo-Garcia JL, Viswanath P, Eriksson P, et al. Metabolic reprogramming in mutant IDH1 glioma cells. PLoS One. 2015;10(2):e0118781.
   PubMed Web of Science ®Google Scholar
• Gerecke C, Schumacher F, Edlich A, et al. Vitamin C promotes decitabine or azacytidine induced DNA hydroxymethylation and subsequent reactivation of the epigenetically silenced tumour suppressor CDKN1A in colon cancer cells. Oncotarget. 2018 Aug 28;9(67):32822–32840.
   PubMedGoogle Scholar
• Mondesir J, Willekens C, Touat M, et al. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. J Blood Med. 2016;7:171–180.
   PubMed Web of Science ®Google Scholar
• Saba HI. Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag. 2007 Oct;3(5):807–817.
   PubMedGoogle Scholar
• Seymour JF, Dohner H, Butrym A, et al. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. BMC Cancer. 2017 Dec 14;17(1):852.
   PubMedGoogle Scholar
• Schuh AC, Döhner H, Pleyer L, et al. Azacitidine in adult patients with acute myeloid leukemia. Crit Rev Oncol Hematol. 2017 Aug;116:159–177.
   PubMed Web of Science ®Google Scholar
• Pleyer L, Dohner H, Dombret H, et al. Azacitidine for front-line therapy of patients with AML: reproducible efficacy established by direct comparison of international phase 3 trial data with registry data from the Austrian Azacitidine registry of the AGMT study group. Int J Mol Sci. 2017 Feb 15;18(2).
   Web of Science ®Google Scholar
• Pleyer L, Greil R. Digging deep into “dirty” drugs - modulation of the methylation machinery. Drug Metab Rev. 2015 May;47(2):252–279.
   PubMed Web of Science ®Google Scholar
• Younes M, Brown RW, Stephenson M, et al. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer. 1997 Sep 15;80(6):1046–1051.
   PubMed Web of Science ®Google Scholar
• Chen X, Lu P, Zhou S, et al. Predictive value of glucose transporter-1 and glucose transporter-3 for survival of cancer patients: A meta-analysis. Oncotarget. 2017 Feb 21;8(8):13206–13213.
   PubMedGoogle Scholar
• Molenaar RJ, Maciejewski JP, Wilmink JW, et al. Wild-type and mutated IDH1/2 enzymes and therapy responses. Oncogene. 2018 Apr;37(15):1949–1960.
   PubMed Web of Science ®Google Scholar
• Ngo B, Van Riper JM, Cantley LC, et al. Targeting cancer vulnerabilities with high-dose vitamin C. Nat Rev Cancer. 2019 May;19(5):271–282.
   PubMed Web of Science ®Google Scholar
• Yun J, Mullarky E, Lu C, et al. Vitamin C selectively kills KRAS/BRAF mutant colorectal cancer cells by targeting GAPDH [10.1126/science.aaa5004]. Science. 2015;350(6266):1391.
   PubMed Web of Science ®Google Scholar
• Sant DW, Mustafi S, Gustafson CB, et al. Vitamin C promotes apoptosis in breast cancer cells by increasing TRAIL expression. Sci Rep. 2018 mar 28;8(1):5306.
   PubMedGoogle Scholar
• Chen J, Guo L, Zhang L, et al. Vitamin C modulates TET1 function during somatic cell reprogramming. Nat Genet. 2013 Dec;45(12):1504–1509.
   PubMed Web of Science ®Google Scholar
• Liu M, Ohtani H, Zhou W, et al. Vitamin C increases viral mimicry induced by 5-aza-2′-deoxycytidine. Proc Nat Acad Sci. 2016;113(37):10238–10244.
   PubMed Web of Science ®Google Scholar
• Schleicher RL, Carroll MD, Ford ES, et al. Serum vitamin C and the prevalence of vitamin C deficiency in the United States: 2003–2004 National Health and Nutrition Examination Survey (NHANES). Am J Clin Nutr. 2009 Nov;90(5):1252–1263.
   PubMed Web of Science ®Google Scholar
• Mayland CR, Bennett MI, Allan K. Vitamin C deficiency in cancer patients. Palliat Med. 2005 Jan;19(1):17–20.
   PubMed Web of Science ®Google Scholar
• Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010 Feb 15;207(2):339–344.
   PubMed Web of Science ®Google Scholar
• Yen KE, Bittinger MA, Su SM, et al. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene. 2010 Dec 9;29(49):6409–6417.
   PubMed Web of Science ®Google Scholar
• Sharen G, Peng Y, Cheng H, et al. Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients. Oncotarget. 2017 Mar 21;8(12):19760–19767.
   PubMedGoogle Scholar
• Gonzalez-Menendez P, Hevia D, Mayo JC, et al. The dark side of glucose transporters in prostate cancer: are they a new feature to characterize carcinomas? Int J Cancer. 2018 Jun 15;142(12):2414–2424.
   PubMed Web of Science ®Google Scholar
• Zhao H, Zhu H, Huang J, et al. The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. Leuk Res. 2018;66:1–7.
   PubMed Web of Science ®Google Scholar
• Carr AC, Maggini S. Vitamin C and immune function. Nutrients. 2017 Nov 3;9(11).
   Web of Science ®Google Scholar
• Ang A, Pullar JM, Currie MJ, et al. Vitamin C and immune cell function in inflammation and cancer. Biochem Soc Trans. 2018 Oct 19;46(5):1147–1159.
   PubMed Web of Science ®Google Scholar
• Nauman G, Gray JC, Parkinson R, et al. Systematic review of intravenous ascorbate in cancer clinical trials. Antioxidants (Basel). 2018 Jul 12;7(7):89.
   PubMedGoogle Scholar
• Kuiper C, Vissers MC. Ascorbate as a co-factor for fe- and 2-oxoglutarate dependent dioxygenases: physiological activity in tumor growth and progression. Front Oncol. 2014;4:359.
   PubMedGoogle Scholar
• Schoenfeld JD, Sibenaller ZA, Mapuskar KA, et al. O2(-) and H2O2-mediated disruption of Fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate. Cancer Cell. 2017 Apr 10;31(4):487–500 e8.
   PubMed Web of Science ®Google Scholar
• Mustafi S, Camarena V, Volmar CH, et al. Vitamin C sensitizes melanoma to BET inhibitors. Cancer Res. 2018 Jan 15;78(2):572–583.
   PubMed Web of Science ®Google Scholar
• Ma Y, Chapman J, Levine M, et al. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 2014 Feb 5;6(222):222ra18.
   PubMed Web of Science ®Google Scholar
• Fernandez SL, Russell DW, Hurlin PJ. Development of human gene reporter cell lines using rAAV mediated homologous recombination. Biol Proced Online. 2007 Dec;24(9):84–90.
   Google Scholar
• Davis M, Pragani R, Popovici-Muller J, et al. ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD). 2010.
   Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1–2):55–63.
   PubMed Web of Science ®Google Scholar
• Berger RS, Ellmann L, Reinders J, et al. Degradation of D-2-hydroxyglutarate in the presence of isocitrate dehydrogenase mutations. Sci Rep. 2019 May 15;9(1):7436.
   PubMedGoogle Scholar
• Schumacher F, Herrmann K, Florian S, et al. Optimized enzymatic hydrolysis of DNA for LC-MS/MS analyses of adducts of 1-methoxy-3-indolylmethyl glucosinolate and methyleugenol. Anal Biochem. 2013 Mar 1;434(1):4–11.
   PubMed Web of Science ®Google Scholar
• Vermes I, Haanen C, Steffens-Nakken H, et al. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 1995 Jul 17;184(1):39–51.
   PubMed Web of Science ®Google Scholar